Literature DB >> 16251231

Prevention of cardiovascular diseases: focus on modifiable cardiovascular risk.

F El Fakiri1, M A Bruijnzeels, A W Hoes.   

Abstract

OBJECTIVE: To determine whether the use of a 20% absolute risk threshold for cardiovascular disease as recommended in current guidelines leads to exclusion of patients with a substantial modifiable risk (> or = 5%).
METHODS: Data collected within the framework of a randomised controlled trial in three primary health care centres located in deprived neighbourhoods were analysed. The 10 year absolute risk and the modifiable part of risk were calculated by using the Framingham risk equation. Among patients with a modifiable risk reduction of > or = 5% (number needed to treat < or = 20) the characteristics and risk factors of patients with an absolute risk > or = 20% and those with an absolute risk < 20% were compared.
RESULTS: 293 patients aged 30-70 years at risk of developing cardiovascular disease were included, of whom 66% were women and 36% were of Dutch origin. Of all patients, 33% had an absolute risk > or = 20% and 61% had a modifiable risk > or = 5%. Of those at > or = 20% absolute risk, a vast majority (98%) had a modifiable risk > or = 5%. Among those with an absolute risk < 20%, 43% had a modifiable risk > or = 5%; this group, who were relatively young and predominantly women, constituted 29% of the entire study population.
CONCLUSIONS: Targeting preventive strategies at a 10 year absolute risk > or = 20% leads to exclusion of a large group of relatively young, predominantly female patients. In total, about one quarter had an absolute risk < 20% but a modifiable risk > or = 5% and should therefore benefit from intervention.

Entities:  

Mesh:

Year:  2005        PMID: 16251231      PMCID: PMC1860680          DOI: 10.1136/hrt.2005.068114

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  30 in total

1.  Joint British recommendations on prevention of coronary heart disease in clinical practice. British Cardiac Society, British Hyperlipidaemia Association, British Hypertension Society, endorsed by the British Diabetic Association.

Authors: 
Journal:  Heart       Date:  1998-12       Impact factor: 5.994

Review 2.  Cardiovascular disease: different strategies for primary and secondary prevention?

Authors:  F D R Hobbs
Journal:  Heart       Date:  2004-10       Impact factor: 5.994

Review 3.  Effect of different antilipidemic agents and diets on mortality: a systematic review.

Authors:  Marco Studer; Matthias Briel; Bernd Leimenstoll; Tracy R Glass; Heiner C Bucher
Journal:  Arch Intern Med       Date:  2005-04-11

4.  Number-needed-to-treat analysis of the prevention of myocardial infarction and death by antidyslipidemic therapy.

Authors:  C M Rembold
Journal:  J Fam Pract       Date:  1996-06       Impact factor: 0.493

5.  Primary prevention of coronary heart disease: guidance from Framingham: a statement for healthcare professionals from the AHA Task Force on Risk Reduction. American Heart Association.

Authors:  S M Grundy; G J Balady; M H Criqui; G Fletcher; P Greenland; L F Hiratzka; N Houston-Miller; P Kris-Etherton; H M Krumholz; J LaRosa; I S Ockene; T A Pearson; J Reed; R Washington; S C Smith
Journal:  Circulation       Date:  1998-05-12       Impact factor: 29.690

Review 6.  [Identification of disadvantaged areas; a system for resource allocation to family practitioners].

Authors:  J van der Velden; P Rasch; S A Reijneveld
Journal:  Ned Tijdschr Geneeskd       Date:  1997-04-05

7.  Systematic review of randomised controlled trials of multiple risk factor interventions for preventing coronary heart disease.

Authors:  S Ebrahim; G D Smith
Journal:  BMJ       Date:  1997-06-07

8.  Lipid-lowering for prevention of coronary heart disease: what policy now?

Authors:  I Ul Haq; L E Ramsay; D M Pickin; W W Yeo; P R Jackson; J N Payne
Journal:  Clin Sci (Lond)       Date:  1996-10       Impact factor: 6.124

Review 9.  Hypertension in the elderly. Implications and generalizability of randomized trials.

Authors:  C D Mulrow; J A Cornell; C R Herrera; A Kadri; L Farnett; C Aguilar
Journal:  JAMA       Date:  1994-12-28       Impact factor: 56.272

Review 10.  [Therapy and prevention of coronary heart diseases through lowering of the serum cholesterol levels; third consensus 'Cholesterol'. Consensus Working Group, CBO].

Authors:  M L Simoons; A F Casparie
Journal:  Ned Tijdschr Geneeskd       Date:  1998-09-19
View more
  3 in total

1.  Different distribution of cardiovascular risk factors according to ethnicity: a study in a high risk population.

Authors:  Fatima El Fakiri; Marc A Bruijnzeels; Marleen M E Foets; Arno W Hoes
Journal:  J Immigr Minor Health       Date:  2008-12

2.  Coping with methodological dilemmas; about establishing the effectiveness of interventions in routine medical practice.

Authors:  Yvonne J F M Jansen; Roland Bal; Marc Bruijnzeels; Marleen Foets; Rianne Frenken; Antoinette de Bont
Journal:  BMC Health Serv Res       Date:  2006-12-13       Impact factor: 2.655

3.  Decision-making using absolute cardiovascular risk reduction and incremental cost-effectiveness ratios: a case study.

Authors:  J A Ker; H Oosthuizen; P Rheeder
Journal:  Cardiovasc J Afr       Date:  2008 Mar-Apr       Impact factor: 1.167

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.